Orchard Therapeutics Gets Swissmedic Approval For Libmeldy In Early-onset MLD

RTTNews | 526 dagar sedan
Orchard Therapeutics Gets Swissmedic Approval For Libmeldy In Early-onset MLD

(RTTNews) - Gene therapy leader Orchard Therapeutics plc (ORTX) announced Monday the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, for the treatment of early-onset metachromatic leukodystrophy (MLD).

MLD is a rare, fatal genetic disorder caused by a mutation in the gene responsible for encoding the enzyme arylsulfatase A (ARSA) leading to neurological damage and developmental regression.

Libmeldy aims to correct the underlying genetic cause of MLD by inserting a working copy of the ARSA gene into the genome of a patients' own HSCs. The genetically modified cells are infused back into the patient, where they can naturally migrate across the blood-brain barrier into the central nervous system, engraft, and express the functional enzyme.

In clinical trials, treatment with Libmeldy resulted in the preservation of cognitive development and maintenance of motor function past ages at which untreated patients showed severe cognitive and motor impairments.

read more
Honda Cuts EV Sales, Investment Targets As It Shifts Focus

Honda Cuts EV Sales, Investment Targets As It Shifts Focus

Honda Motor Co., Ltd. announced Tuesday that it is realigning automobile business strategy, with a cut in planned electric vehicle or EV sales ratio, and investment for automobile electrification due to the recent market slowdown. Meanwhile, Honda expects a minimal increase in investment related to Hybrid Electric Vehicle or HEV business.
RTTNews | 36 minuter sedan
U.S. Dollar Slides Amid U.S. Tariff Uncertainty

U.S. Dollar Slides Amid U.S. Tariff Uncertainty

The U.S. dollar weakened against other major currencies in the European session on Tuesday, due to fiscal and economic concerns amid uncertainties about U.S. tariffs.
RTTNews | 3h 32minuter sedan
Home Depot Q1 Profit Misses Market, But Sales Beat; Backs Outlook; Stock Up

Home Depot Q1 Profit Misses Market, But Sales Beat; Backs Outlook; Stock Up

Home Depot Inc. reported Tuesday weak first-quarter profit below market estimates, while sales grew from last year and beat the Street view with slightly higher comparable sales in the U.S. Further, the home improvement retailer maintained its fiscal 2025 guidance, expecting weak earnings, but higher sales and comparable sales. In the pre-market activity on the NYSE, Home Depot shares were gaining
RTTNews | 4h 39minuter sedan
CAC 40 Modestly Higher

CAC 40 Modestly Higher

The French market is modestly higher in cautious trade on Tuesday with investors closely following the developments on the geopolitical front. Tensions between Russia and Ukraine linger despite an announcement from U.S. President Donald Trump that the two nations would soon begin ceasefire negotiations.
RTTNews | 4h 52minuter sedan